We are Anchiano Therapeutics, a novel-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.
Focus on discovering and developing therapies for patients with cancer in areas of unmet need
Initial program: genetic therapy for early stage bladder cancer
Utilizes technology licensed from Hebrew University
Founded in 2004; based in Cambridge and Jerusalem
New CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure
$45 million (end Q3 2018)
Approximate market capitalization
Publicly traded in Israel (TASE:ANCN)
$11 million (end Q3 2018)
cash, no debt
Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the CODEX Trial, opened in December of 2018 and is recruiting patients now (link to ClinicalTrials.gov).
We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Tel Aviv Stock Exchange (TASE:ANCN).
Our R&D activities build upon the discovery by Professor Avraham Hochberg, of the Hebrew University of Jerusalem, of the human H19 gene. It has been shown that the gene is expressed in over forty different forms of cancer, including especially bladder cancer, while being quiescent in most normal adult tissues. H19-based therapy is designed to be a highly selective method of killing cancer cells that spares normal bladder tissue.
We are dedicated to the discovery, development and commercialization of effective and safe treatments for cancer that address significant unmet medical needs and provide clinical benefits to millions of patients worldwide.